NASDAQ$HOLX

Hologic Inc · Q1 2024 earnings

Q1 2024 earnings · · Investor relations

Briefing

Hologic's first quarter of fiscal year 2024 earnings were announced, with revenue of $1,013.1 million and GAAP diluted EPS of $1.03, both exceeding guidance.

Hologic reported a revenue of $1,013.1 million for the first quarter of fiscal year 2024, a decrease of 5.7% compared to the prior year, but exceeded their guidance. GAAP diluted EPS was $1.03 and non-GAAP diluted EPS was $0.98, also exceeding guidance. Total organic revenue growth excluding COVID-19 was 5.2% in constant currency.

  • Revenue of $1,013.1 million decreased (5.7%) for the quarter, or (6.4%) in constant currency, primarily driven by lower sales of COVID-19 assays compared to the prior year period.
  • Excluding COVID-19 revenues, total organic revenue grew 6.1%, or 5.2% on a constant currency basis despite the prior year period including four extra selling days.
  • Breast Health revenue increased 13.0%, or 12.2% in constant currency, primarily due to higher capital equipment revenue compared to the prior year period as supply chain headwinds impacted our ability to manufacture sufficient units to meet demand in fiscal Q1 2023.
  • Cash flow from operations remained strong in the first quarter at $220.0 million.

Headline financials

Total Revenue

$1.01B

Previous: $1.07B-5.7%
EPS

$1.03

Previous: $1.07-3.7%
GAAP Gross Margin

56.0%

No prior period
Non-GAAP Gross Margin

60.8%

No prior period
Operating Margin

19.6%

No prior period
Non-GAAP Operating Margin

28.5%

No prior period
Net Margin

24.3%

No prior period
Non-GAAP Net Margin

23.3%

No prior period
Capital Expenditures

-$38M

No prior period
Net Income

$247M

Previous: $187M+31.5%
Operating Income

$198M

Previous: $262M-24.5%
Gross Profit

$568M

Previous: $618M-8.2%
Cash & Equivalents

$1.93B

Previous: $2.44B-20.9%
Total Assets

$8.47B

Previous: $9.29B-8.8%
R&D Expense

$66.8M

No prior period
Stock-Based Comp

$28.7M

Previous: $20.5M+40.0%

Revenue & EPS history

Hologic · Revenue · Quarterly

$1.01B

Q1 2024-5.7%vs Q1 2023
Beat estimate in 14 of 16 quarters(88%)
ActualEstimate

Revenue by segment

Hologic · $769M total across 2 segments · Q4 2023

  • Diagnostics
    $416M-20.1%
  • Breast Health
    $353M+28.2%

Forward guidance

Hologic is guiding for the second quarter of fiscal year 2024 with revenue between $990 million and $1,010 million and non-GAAP EPS between $0.95 and $1.00. For the full fiscal year 2024, Hologic is guiding for revenue between $3,990 million and $4,065 million and non-GAAP EPS between $3.97 and $4.12.

Tailwinds

  • Revenue between $3,990 and $4,065 million for fiscal year 2024.
  • GAAP EPS between $3.52 and $3.67 for fiscal year 2024.
  • Non-GAAP EPS between $3.97 and $4.12 for fiscal year 2024.
  • Revenue between $990 and $1,010 million for Q2 2024.
  • GAAP EPS between $0.77 and $0.82 for Q2 2024.

Headwinds

  • Fiscal 2024 has four fewer selling days compared to fiscal 2023, which is estimated to be a headwind of more than 100 bps for the full year.
  • Revenue guidance for Q2 2024 reflects a decrease of (3.6%) to (1.6%).
  • Constant Currency Revenue guidance for Q2 2024 reflects a decrease of (3.7%) to (1.8%).
  • GAAP EPS guidance for Q2 2024 reflects a decrease of (11.5%) to (5.7%).
  • Non-GAAP EPS guidance for Q2 2024 reflects a decrease of (10.4%) to (5.7%).

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2024

Historical avgQ1 2024

-0.5%

Avg return

Earnings day

+0.2%

Avg return

5 days after

-0.1%

Avg return

30 days after

49%

35 / 72 earnings

Positive

+12.3%

Q3 2020

Best reaction

-11.4%

Q2 2012

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026
Q1 2026+0.0%-0.6%+0.7%
Q4 2025+0.1%+0.1%+0.9%
Q3 2025+2.8%+4.4%+3.3%
Q2 2025-5.6%-3.2%+8.5%
Q1 2025-10.1%-11.4%-11.3%
Q4 2024-4.3%-4.3%-6.6%
Q3 2024+4.9%+6.4%+2.2%
Q2 2024+0.3%-0.2%-3.3%
Q1 2024-2.7%-0.4%-1.1%
Q4 2023+5.7%+5.4%+0.1%
Q3 2023-5.1%-5.9%-5.4%
Q2 2023-2.4%-2.6%-8.3%
Q1 2023+3.8%+3.6%-1.1%
Q4 2022+10.8%+12.4%+13.8%
Q3 2022+1.0%+1.3%-3.4%
Q2 2022+1.2%+3.4%+9.8%
Q1 2022+4.0%+3.8%+2.4%
Q4 2021-3.3%-5.9%-0.3%
Q3 2021+2.3%+5.0%+9.7%
Q2 2021-9.1%-9.9%-13.4%
Q1 2021+1.7%+11.2%-3.3%
Q4 2020+6.6%-5.0%+1.7%
Q3 2020+12.3%+14.8%-2.8%
Q2 2020+2.9%+2.6%+8.9%
Q1 2020-0.7%-1.8%-13.7%
Q4 2019-4.0%+8.8%+10.3%
Q3 2019-1.3%-6.5%-4.1%
Q2 2019-0.1%+0.7%-5.1%
Q1 2019+0.6%-0.5%+8.6%
Q4 2018+4.9%+1.2%+3.7%
Q3 2018-3.5%-1.9%-7.5%
Q2 2018-6.9%-6.8%-3.9%
Q1 2018-6.7%-6.6%-2.2%
Q4 2017+0.4%+2.9%+8.1%
Q3 2017-9.3%-11.3%-12.5%
Q2 2017-4.3%-5.1%-2.0%
Q1 2017-2.6%-2.9%+1.8%
Q4 2016+4.3%+8.5%+6.3%
Q3 2016+3.9%+5.8%+5.3%
Q2 2016-10.0%
Q1 2016-9.2%
Q4 2015+0.6%
Q3 2015+8.6%
Q2 2015+2.1%
Q1 2015+5.1%
Q4 2014-1.7%
Q3 2014+2.1%
Q2 2014+8.1%
Q1 2014-5.9%
Q4 2013-6.9%
Q3 2013-0.2%
Q2 2013+0.1%
Q1 2013-4.1%
Q4 2012-0.3%
Q3 2012-0.4%
Q2 2012-11.4%
Q1 2012+5.2%
Q4 2011-4.0%
Q3 2011-3.9%
Q2 2011-0.6%
Q1 2011+0.0%
Q4 2010+1.2%
Q3 2010+1.2%
Q2 2010-2.6%
Q1 2009-2.8%
Q1 2010-1.1%
Q2 2009+2.9%
Q4 2007+2.9%
Q4 2009+2.9%
Q3 2009-3.0%
Q3 2008-3.0%
Q4 2008-3.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro